NICE TAs

12/02/2026
TA1129: Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
12/02/2026
TA1131: Obinutuzumab with mycophenolate mofetil for treating lupus nephritis
11/02/2026
TA1130: Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer
04/02/2026
TA1128: Targeted-release budesonide for treating primary IgA nephropathy
04/02/2026
TA1127: Nivolumab with chemotherapy for neoadjuvant treatment then alone for adjuvant treatment of resectable non-small-cell lung cancer
28/01/2026
TA1126: natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy
27/01/2026
TA972: sirolimus for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over (terminated appraisal)
27/01/2026
TA1125: pembrolizumab with pemetrexed and platinum-based chemotherapy for untreated unresectable advanced malignant pleural mesothelioma (terminated appraisal)
27/01/2026
TA1124: concizumab for treating haemophilia A or B in people 12 years and over with factor inhibitors (terminated appraisal)
26/01/2026
TA1123: Depemokimab for treating chronic rhinosinusitis with nasal polyps in adults (terminated appraisal)
21/01/2026
TA1122: Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer
14/01/2026
TA1121: Acoramidis for treating transthyretin amyloidosis with cardiomyopathy
13/01/2026
TA1117: Dostarlimab with platinum-containing chemotherapy for treating primary advanced or recurrent endometrial cancer with microsatellite stability or mismatch repair proficiency
08/01/2026
TA1120: Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645)
07/01/2026
TA1118: Entrectinib for treating NTRK fusion-positive solid tumours (terminated appraisal)
07/01/2026
TA1119: Venetoclax with obinutuzumab for untreated chronic lymphocytic leukaemia when there is no 17p deletion or TP53 mutation and FCR or BR are suitable (MA partial review of TA663)
11/12/2025
TA1116: Obecabtagene autoleucel for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia
10/12/2025
TA1115: Vutrisiran for treating transthyretin amyloidosis with cardiomyopathy
03/12/2025
TA1114: Talquetamab for treating relapsed and refractory multiple myeloma after 3 or more treatments
03/12/2025
TA1113: Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse large B-cell lymphoma